SynthesisPloS one2018
Intermittent furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials.
Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Intermittent furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials.PloS one · 2018Pooled it
- Effect of 3% saline and furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects - a randomized controlled trial.BMC nephrology · 2019Trial
- From mechanisms to clinical practice: a review of diuretic therapy in pediatric nephrology.Pediatric nephrology (Berlin, Germany) · 2026Review
- Low-dose loop diuretics improve survival and renal function in cancer patients with early-stage sepsis-associated acute kidney injury.Renal failure · 2025Article
- Prevention and Management of Perioperative Acute Kidney Injury: A Narrative Review.Diseases (Basel, Switzerland) · 2025Review
- Management of non-Cardiac Organ Failure in cardiogenic shock.American heart journal plus : cardiology research and practice · 2025Article
- Association between the use of loop diuretics and prognosis in critically ill patients with acute kidney injury: a retrospective propensity score-matched cohort study.International urology and nephrology · 2025Article
- Understanding fluid dynamics and renal perfusion in acute kidney injury management.Journal of clinical monitoring and computing · 2025Review
- Observational
- Furosemide exacerbated the impairment of renal function, oxygenation and medullary damage in a rat model of renal ischemia/reperfusion induced AKI.Intensive care medicine experimental · 2023Article
- Management of Acute Kidney Injury in Critically Ill Children.Indian journal of pediatrics · 2023Review
- Contemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome: JACC Council Perspectives.Journal of the American College of Cardiology · 2020Review
- A "crush" course on rhabdomyolysis: risk stratification and clinical management update for the perioperative clinician.Journal of anesthesia · 2020Review
- Association between furosemide administration and outcomes in critically ill patients with acute kidney injury.Critical care (London, England) · 2020Article
- Impact of furosemide on mortality and the requirement for renal replacement therapy in acute kidney injury: a systematic review and meta-analysis of randomised trials.Annals of intensive care · 2019Article
- Effect of continuous furosemide infusion on outcome of acute kidney injury.Pakistan journal of medical sciences · 2019Article
- Loop diuretic use in patients with AKI: different severity, different response.Critical care (London, England) · 2018Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFurosemide is the most common loop diuretic used worldwide. The off-label administration of furosemide bolus(es) for the prevention or to reverse acute kidney injury (AKI) is widespread but not supported by available evidence. We conducted a meta-analysis of randomized trials (RCTs) to investigate whether bolus furosemide to prevent or treat AKI is detrimental on patients' survival.
methodsElectronic databases were searched through October 2017 for RCTs comparing bolus furosemide administration versus any comparator in patients with or at risk for AKI. The primary endpoint was all-cause longest follow-up mortality. Secondary endpoints included new or worsening AKI, receipt of renal replacement therapy, length of hospital stay, and peak serum creatinine after randomization.
resultsA total of 28 studies randomizing 3,228 patients were included in the analysis. We found no difference in mortality between the two groups (143/892 [16%] in the furosemide group versus 141/881 [16%] in the control group; odds ratio [OR], 0.84; 95% confidence interval [CI], 0.63 to 1.13; p = 0.25). No significant differences in secondary outcomes were found. A significant improvement in survival was found in the subgroup of patients receiving furosemide bolus(es) as a preventive measure (43/613 [7.0%] versus 67/619 [10.8%], OR 0.62; 95% CI, 0.41 to 0.94; p = 0.03).
conclusionsIntermittent furosemide administration is not associated with an increased mortality in patients with or at risk for AKI, although it may reduce mortality when used as a preventive measure. Future high-quality RCTs are needed to define the role of loop diuretics in AKI prevention and management.
trial registrationThe study protocol was registered on PROSPERO database for systematic reviews (Registration no. CRD42017078607 - http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017078607).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.